Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249587 | 0.90 | HRH3 (0.46) | RAB9AMAPK1HRH3ADRA1AKCNH2 | |
| SCHEMBL10249762 | 0.90 | HRH3 (0.49) | HRH3ADRA1AKCNH2ESR1HRH1 | |
| SCHEMBL10097291 | 0.85 | HRH3 (0.40) | HRH3KCNH2HRH2HRH1 | |
| SCHEMBL10249443 | 0.82 | LTA4H (0.47) | RAB9AADRA1AHTR5AESR1ESR2 | |
| SCHEMBL13152111 | 0.80 | GRIK2 (0.38) | RAB9AMAPK1NPC1 | |
| SCHEMBL13151837 | 0.80 | GRIK2 (0.41) | MAPK1 | |
| SCHEMBL13152603 | 0.80 | MAPT (0.44) | MAPK1 | |
| SCHEMBL10097401 | 0.79 | JAK1 (0.39) | HRH3ESR1ESR2 | |
| SCHEMBL10253105 | 0.79 | MET (0.41) | ADRA1ADRD3HRH2HRH1 | |
| SCHEMBL12334400 | 0.79 | HRH3 (0.51) | HRH3ADRA1AKCNH2ESR1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | RAB9A 3975/4885MAPK1 4384/4885HRH3 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.